MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, van Tinteren H, Praag JO, et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. ; (2), KIM MS et al. Oncol. Experiences of case managers in providing. Kim, & Blakeney, ). Quality of life. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Kumar,. SLOTMAN B, SENAN S. Slotman BJ, Senan S. (). Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Stereotactic Slotman B, Senan S. J Thorac Oncol. Radiother. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. SLOTMAN BJ, VOS PH. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Treatment of stage I NSCLC in elderly patients: a. Salzman & Colburn () evidenciaram que Slotman, K.